#ESMO26 LBA3
— Masahiro TORASAWA, MD. PhD. (@M_Torasawa) October 24, 2026
🚨 DeLLphi-305: Phase 3 results in ES-SCLC!
Tarlatamab + durvalumab vs durvalumab as 1L maintenance (n=563)
✅ OS: 21.1 vs 12.7 mo (HR 0.42)
✅ PFS: 7.4 vs 1.9 mo (HR 0.34)
✅ ORR: 26.4% vs 4.1%
⚠️ CRS: 49.6% (G≥3: 0.4%)
⚠️ ICANS: 1.1%
Impressive survival… https://t.co/iR7a16P0ty pic.twitter.com/G6k9GhugDp